Back to top

vaccines: Archive

Zacks Equity Research

Moderna (MRNA) Posts Pipeline Progress, Secures Blackstone Funding

Moderna (MRNA) posts data on three experimental vaccines and intends to advance them to late-stage studies. It also secures $750 million in funding from Blackstone to advance its influenza program.

MRNANegative Net Change ANIPPositive Net Change ADMAPositive Net Change GLPGNegative Net Change

Zacks Equity Research

Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study

Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.

PFENegative Net Change MRNANegative Net Change NVAXPositive Net Change BNTXNegative Net Change

Zacks Equity Research

Merck's (MRK) Keytruda-Lynparza Combo Fails 2nd Lung Cancer Study

Merck's attempt to use the Keytruda-Lynparza combination in certain non-small cell lung cancer patients has come up short with a second pivotal study failure.

AZNNegative Net Change MRKNegative Net Change ANIPPositive Net Change ADMAPositive Net Change

Zacks Equity Research

GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US

GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.

AZNNegative Net Change GSKPositive Net Change TEVAPositive Net Change ADMAPositive Net Change

Zacks Equity Research

AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US

AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.

AZNNegative Net Change GSKPositive Net Change TEVAPositive Net Change ADMAPositive Net Change

Zacks Equity Research

Why Moderna (MRNA) Stock Price Was Up 9% on Monday

Moderna (MRNA) surges amid initiation reports of a phase II/III study on Merck-partnered experimental cancer therapy to treat patients with cutaneous squamous cell carcinoma, a form of skin cancer.

MRKNegative Net Change MRNANegative Net Change ANIPPositive Net Change ADMAPositive Net Change

Zacks Equity Research

Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales

Emergent (EBS) reports mixed earnings for fourth-quarter 2023. The company signs a forbearance agreement with its lenders, effective till April 2023-end.

GSKPositive Net Change EBSNegative Net Change ANIPPositive Net Change ADMAPositive Net Change